Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13D Filing: Adage Capital Management and Inotek Pharmaceuticals Corp (ITEK)

Page 1 of 13

Inotek Pharmaceuticals Corp (NASDAQ:ITEK): Phill Gross And Robert Atchinson’s Adage Capital Management filed an amended 13D.

You can check out Adage Capital Management’s latest holdings and filings here.

Please follow Adage Capital Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Adage Capital Management or update its stock holdings.

Phill Gross And Robert Atchinson
Phill Gross And Robert Atchinson
Adage Capital Management

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Adage Capital Partners 0 1,500,000 0 1,500,000 1,500,000 5.55%
Adage Capital Partners GP 0 1,500,000 0 1,500,000 1,500,000 5.55%
Adage Capital Advisors 0 1,500,000 0 1,500,000 1,500,000 5.55%
Robert Atchinson 0 1,500,000 0 1,500,000 1,500,000 5.55%
Phillip Gross 0 1,500,000 0 1,500,000 1,500,000 5.55%
Phill Gross And Robert Atchinson
Phill Gross And Robert Atchinson
Adage Capital Management

Page 1 of 13 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. )*

Inotek Pharmaceuticals
Corporation

(Name of Issuer)

Common Stock,
par value $0.01 per share

(Title of Class of Securities)

45780V102

(CUSIP Number)
Robert Atchinson
Adage Capital Partners GP, L.L.C.
200 Clarendon Street, 52nd Floor
Boston, MA 02116

(617) 867-2800

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

September
26, 2017

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule
13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule
13d-1(f) or Rule 13d-1(g), check the following box. [ ]

(Page 1 of 13 Pages)

______________________________

* The remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing
information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall
not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or
otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

Follow Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)
Trade (NASDAQ:RCKT) Now!
Page 1 of 13
Loading...